Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 201 articles:
HTML format



Single Articles


    March 2024
  1. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
    Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
    BJU Int. 2024;133:324-331.
    PubMed     Abstract available


    February 2024
  2. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
    Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
    PubMed    


  3. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
    During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
    BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
    PubMed     Abstract available


  4. ZUUR LG, de Barros HA, van Oosterom MN, Berrens AC, et al
    (99m) TcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial.
    BJU Int. 2024 Feb 12. doi: 10.1111/bju.16297.
    PubMed     Abstract available


  5. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
    Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
    BJU Int. 2024;133:197-205.
    PubMed     Abstract available


  6. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
    International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
    BJU Int. 2024;133:179-187.
    PubMed     Abstract available


  7. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
    How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
    BJU Int. 2024;133 Suppl 3:13-14.
    PubMed    


  8. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
    The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    BJU Int. 2024;133 Suppl 3:39-47.
    PubMed     Abstract available


    January 2024
  9. SANCHEZ-SALAS R
    Candid choices: optimising patient selection in prostate cancer focal therapy.
    BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
    PubMed    


  10. BESIROGLU H
    Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
    PubMed    


  11. TALWAR R, Akinsola O, Penson DF
    What is cancer? A focus on Grade Group 1 prostate cancer.
    BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
    PubMed     Abstract available


  12. ALBERTSEN PC, Bjerner LJ, Pasovic L, Muller S, et al
    Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
    BJU Int. 2024;133:104-111.
    PubMed     Abstract available


  13. MAYOR N, Eldred-Evans D, Tam H, Sokhi H, et al
    Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
    BJU Int. 2024;133:112-117.
    PubMed     Abstract available


    December 2023
  14. GUERCIO A, Franco G, Lombardo R, De Nunzio C, et al
    LETTER TO THE EDITOR Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16263.
    PubMed    


  15. LENI R, Roscigno M, Barzaghi P, La Croce G, et al
    Medium-term follow up of active surveillance for early prostate cancer at a non-academic institution.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16259.
    PubMed     Abstract available


    November 2023
  16. GABRIEL J, Gabriel A, Shafik L, Alanbuki A, et al
    AI in the urology MDM: can ChatGPT suggest EAU guideline-recommended prostate cancer treatments?
    BJU Int. 2023 Nov 27. doi: 10.1111/bju.16240.
    PubMed    


  17. SHANMUGASUNDARAM R, Saad J, Heyworth A, Wong V, et al
    Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    BJU Int. 2023 Nov 9. doi: 10.1111/bju.16115.
    PubMed     Abstract available


    October 2023
  18. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
    CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
    PubMed     Abstract available


  19. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
    Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
    BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
    PubMed     Abstract available


  20. GEBOERS B, Meijer D, Counter W, Blazevski A, et al
    PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16207.
    PubMed     Abstract available


  21. TISSOT S, Wynn J, Tran V, Farag M, et al
    Re-defining (18) F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology.
    BJU Int. 2023;132:411-419.
    PubMed     Abstract available


  22. BOEVE LMS, Bloemendal FT, de Bie KCC, van Haarst EP, et al
    Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated.
    BJU Int. 2023;132:397-403.
    PubMed     Abstract available


    September 2023
  23. LEHNER F, Crippa A, Sigg S, Eberli D, et al
    Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16181.
    PubMed     Abstract available


  24. JALLOH M, Cassell A, Niang L, Rebbeck T, et al
    Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16178.
    PubMed     Abstract available


  25. PATTENDEN TA, Thangasamy IA, Ong WL, Samaranayke D, et al
    Barriers and enablers of active surveillance for prostate cancer - a qualitive study of clinicians.
    BJU Int. 2023 Sep 11. doi: 10.1111/bju.16176.
    PubMed     Abstract available


  26. KHANNA Y, Chinni V, Gnanasambantham K, O'Sullivan R, et al
    Can (68) Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?
    BJU Int. 2023;132:321-328.
    PubMed     Abstract available


    August 2023
  27. BODAR YJL, Boeve LMS, van Leeuwen PJ, Baars PC, et al
    Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer.
    BJU Int. 2023 Aug 24. doi: 10.1111/bju.16167.
    PubMed     Abstract available


  28. DAVIK P, Remmers S, Elschot M, Roobol MJ, et al
    Performance of MRI-based Prostate Cancer Risk Calculators and decision strategies in two large European medical centres.
    BJU Int. 2023 Aug 22. doi: 10.1111/bju.16163.
    PubMed     Abstract available


  29. BERNARDINO R, Sayyid RK, Leao R, Zlotta AR, et al
    Increasing Trends of Utilizing Active Surveillance for Gleason 7 (3+4) Prostate Cancer.
    BJU Int. 2023 Aug 22. doi: 10.1111/bju.16162.
    PubMed    


  30. SOLANKI AA, Yoo RK, Adams W, Davicioni E, et al
    F-SHARP: A Phase I/II Trial of Focal Salvage HDR Brachytherapy for Radiorecurrent Prostate Cancer.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16150.
    PubMed     Abstract available


  31. LAUGHLIN BS, Anderson JD, Hobbis D, Armstrong M, et al
    Energy Use in Moderate Hypofractionation and Stereotactic Body Radiotherapy for Prostate Cancer.
    BJU Int. 2023 Aug 8. doi: 10.1111/bju.16151.
    PubMed    


  32. FURRER MA, Sathianathen N, Gahl B, Corcoran NM, et al
    Oncological outcomes after attempted nerve sparing radical prostatectomy in patients with high-risk prostate cancer are comparable to standard non-nerve sparing radical prostatectomy: a longitudinal long-term propensity-matched single-centre study.
    BJU Int. 2023 Aug 7. doi: 10.1111/bju.16126.
    PubMed     Abstract available



  33. AUA and SUO publish guideline regarding early detection of prostate cancer | Hormone treatment for biochemical recurrence following definitive therapy of prostate cancer | World-famous surgical museum reopens following multimillion pound renovation.
    BJU Int. 2023;132:120-121.
    PubMed    


    July 2023
  34. ALTERBECK M, Thimansson E, Bengtsson J, Baubeta E, et al
    A pilot study of an organised population-based testing programme for prostate cancer.
    BJU Int. 2023 Jul 31. doi: 10.1111/bju.16143.
    PubMed     Abstract available


  35. CHEN K, Ong S, Vasundhara K, Mun CK, et al
    Is Genetic testing coming of age in advanced prostate cancer?
    BJU Int. 2023 Jul 27. doi: 10.1111/bju.16139.
    PubMed    


  36. SAYYID RK, Klaassen Z, Berlin A, Roy S, et al
    Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
    BJU Int. 2023 Jul 17. doi: 10.1111/bju.16130.
    PubMed     Abstract available


  37. SAYYID RK, Bernardino R, Al-Daqqaq Z, Tiwari R, et al
    Mesorectal Nodal Metastasis with Seminal Vesicle Invasion in Biochemically Recurrent Prostate Cancer.
    BJU Int. 2023 Jul 11. doi: 10.1111/bju.16123.
    PubMed     Abstract available


  38. MASSIE C, Gnanapragasam VJ, Barrett T, Warren A, et al
    Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.
    BJU Int. 2023 Jul 10. doi: 10.1111/bju.16101.
    PubMed    


  39. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
    BJU Int. 2023 Jul 8. doi: 10.1111/bju.16122.
    PubMed     Abstract available


  40. DE PABLOS-RODRIGUEZ P, Claps F, Rebez G, Crespo NV, et al
    Personalized Indocyanine-guided lymphadenectomy for prostate cancer. A randomized Clinical Trial.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16117.
    PubMed     Abstract available


  41. CUSSENOT O, Cancel-Tassin G, Rao SR, Woodcock DJ, et al
    Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16120.
    PubMed     Abstract available


  42. YANAGISAWA T, Kawada T, Mori K, Shim SR, et al
    Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
    BJU Int. 2023 Jul 3. doi: 10.1111/bju.16106.
    PubMed     Abstract available



  43. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    PubMed    


  44. HILL GT, Jeyanthi M, Coomer W, Bryant RJ, et al
    Same-day discharge robot-assisted laparoscopic prostatectomy: feasibility, safety and patient experience.
    BJU Int. 2023;132:92-99.
    PubMed     Abstract available


    June 2023
  45. LIGHT A, Peters M, Reddy D, Kanthabalan A, et al
    External validation of a risk model predicting failure of salvage focal ablation for prostate cancer.
    BJU Int. 2023 Jun 29. doi: 10.1111/bju.16102.
    PubMed     Abstract available


  46. JAIN A, Nassour AJ, Symons JL, Chung A, et al
    The effect of different assays on prostate-specific antigen testing.
    BJU Int. 2023;131:689-691.
    PubMed    


  47. KANEKO M, Medina LG, Lenon MSL, Sayegh AS, et al
    Transperineal magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy under local anaesthesia: the 'double-freehand' technique.
    BJU Int. 2023;131:770-774.
    PubMed    


  48. BRYANT RJ, Yamamoto H, Eddy B, Kommu S, et al
    Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique.
    BJU Int. 2023;131:694-704.
    PubMed     Abstract available


  49. JIA Z, Chen Z, Chang Y, Wu C, et al
    Sustainable functional urethral reconstruction improves early urinary continence after robot-assisted radical prostatectomy: a randomised controlled trial.
    BJU Int. 2023;131:720-728.
    PubMed     Abstract available


  50. FAINBERG J
    Focal therapy using irreversible electroporation: reported successes, with clear limitations, in both primary and salvage settings.
    BJU Int. 2023;131 Suppl 4:34-35.
    PubMed    


    May 2023
  51. LIGHT A, Sarphie DF, Mian R, Li X, et al
    The Leukocyte ImmunoTest for identifying radiorecurrent prostate cancer: a pilot study.
    BJU Int. 2023 May 11. doi: 10.1111/bju.16043.
    PubMed    



  52. Issues related to prostate cancer management.
    BJU Int. 2023;131:518-519.
    PubMed    


  53. MEISSNER VH, Simson BW, Dinkel A, Schiele S, et al
    Treatment decision regret in long-term survivors after radical prostatectomy: a longitudinal study.
    BJU Int. 2023;131:623-630.
    PubMed     Abstract available


    April 2023
  54. WEI G, Ranasinghe W, Evans M, Bolton D, et al
    Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry.
    BJU Int. 2023 Apr 26. doi: 10.1111/bju.15980.
    PubMed     Abstract available


  55. CASTELLO A, Rodriguez-Barranco M, Perez-Gomez B, Chirlaque MD, et al
    High adherence to Western dietary pattern and prostate cancer risk: findings from the EPIC-Spain cohort.
    BJU Int. 2023 Apr 19. doi: 10.1111/bju.16001.
    PubMed     Abstract available


  56. ANDRING LM, Abu-Gheida I, Bathala T, Yoder AK, et al
    Definitive local therapy for T4 prostate cancer associated with improved local control and survival.
    BJU Int. 2023 Apr 14. doi: 10.1111/bju.16027.
    PubMed     Abstract available


  57. LOPEZ JF, Bryant RJ
    The 'Rapid Access Prostate Imaging and Diagnosis' (RAPID) diagnostic pathway: what is the rush?
    BJU Int. 2023;131:377-379.
    PubMed    


  58. KANAGARAJAH A, Hogan D, Yao HH, Dundee P, et al
    A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy.
    BJU Int. 2023;131:408-423.
    PubMed     Abstract available


  59. SHORE ND, Stenzl A, Pieczonka C, Klaassen Z, et al
    Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
    BJU Int. 2023;131:452-460.
    PubMed     Abstract available


    March 2023
  60. LAZZERI M, Fasulo V, Tinterri C
    Eve's and Adam's rib for prostate cancer screening.
    BJU Int. 2023 Mar 15. doi: 10.1111/bju.15999.
    PubMed    


  61. YAXLEY JW
    Focal irreversible electroporation for treatment of primary and radio-recurrent prostate cancer - the evidence is mounting!
    BJU Int. 2023 Mar 6. doi: 10.1111/bju.15987.
    PubMed    



  62. Prostate-specific antigen for prostate cancer screening.
    BJU Int. 2023;131:266.
    PubMed    


  63. MOROTE J, Pye H, Campistol M, Celma A, et al
    Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
    BJU Int. 2023 Mar 1. doi: 10.1111/bju.15998.
    PubMed     Abstract available


    February 2023
  64. STROOMBERG HV, Andersen MCM, Helgstrand JT, Larsen SB, et al
    Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result.
    BJU Int. 2023 Feb 27. doi: 10.1111/bju.15997.
    PubMed     Abstract available


  65. MA TM, Czernin J, Felix C, Alano R, et al
    LUNAR: a randomized phase 2 study of (177) Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol).
    BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988.
    PubMed     Abstract available


  66. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    BJU Int. 2023;131:227-235.
    PubMed     Abstract available


    January 2023
  67. VICKERS A
    Do not treat Bill Gates for prostate cancer! Algorithmic bias and causality in medical prediction.
    BJU Int. 2023 Jan 30. doi: 10.1111/bju.15951.
    PubMed    


  68. CUSSENOT O, Renard-Penna R, Montagne S, Ondet V, et al
    Clinical performance of MRI & biomarkers for prostate cancer diagnosis in men at high genetic risk.
    BJU Int. 2023 Jan 17. doi: 10.1111/bju.15968.
    PubMed     Abstract available


  69. GEBOERS B, Scheltema MJ, Blazevski A, Katelaris A, et al
    Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    BJU Int. 2023 Jan 3. doi: 10.1111/bju.15948.
    PubMed     Abstract available


    December 2022
  70. HANSEN RS, Biorn SH, Birk-Korch JB, Sheikh SP, et al
    Prevalence of prostate cancer in men with haematuria: A systematic review and meta-analysis.
    BJU Int. 2022 Dec 15. doi: 10.1111/bju.15950.
    PubMed     Abstract available


  71. BLAZEVSKI A, Geboers B, Scheltema MJ, Gondoputro W, et al
    Salvage irreversible electroporation for radio recurrent prostate cancer - The prospective FIRE trial.
    BJU Int. 2022 Dec 10. doi: 10.1111/bju.15947.
    PubMed     Abstract available


  72. SCHELTEMA MJ, Geboers B, Blazevski A, Doan P, et al
    Median 5-year outcomes of primary focal irreversible electroporation for localized prostate cancer.
    BJU Int. 2022 Dec 10. doi: 10.1111/bju.15946.
    PubMed     Abstract available


  73. KOSTER KL, Zumstein V, Suveg K, Jochum W, et al
    Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
    BJU Int. 2022 Dec 5. doi: 10.1111/bju.15847.
    PubMed    


  74. BASS EJ, Ahmed HU
    Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3.
    BJU Int. 2022 Dec 5. doi: 10.1111/bju.15859.
    PubMed    


  75. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    PubMed     Abstract available


    November 2022
  76. HOGENHOUT R, Osses DF, Alberts AR, Buizer-Rijksen HG, et al
    Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
    BJU Int. 2022 Nov 21. doi: 10.1111/bju.15933.
    PubMed     Abstract available


  77. KELLY R, Jensen A, Karunaratna N, Wong S, et al
    PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC).
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15930.
    PubMed    


  78. DOAN P, Counter W, Papa N, Sheehan-Dare G, et al
    Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer.
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15929.
    PubMed     Abstract available


  79. CUSSENOT O, Cancel-Tassin G, Comperat E, Benbouzid S, et al
    Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?
    BJU Int. 2022;130:582-585.
    PubMed    


  80. VAN DER SLOT MA, den Bakker MA, Tan TSC, Remmers S, et al
    NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
    BJU Int. 2022;130:628-636.
    PubMed     Abstract available


  81. LAWRENTSCHUK N
    Funding of all issues related to prostate cancer treatment should be a priority and have equal access - a key to survivorship.
    BJU Int. 2022;130 Suppl 3:4.
    PubMed    


  82. YAXLEY WJ, Mackean J, Desai DJ, Tsang G, et al
    Oncological and urinary outcomes following low-dose-rate brachytherapy with a median follow-up of 11.8 years.
    BJU Int. 2022;130 Suppl 3:40-45.
    PubMed     Abstract available


  83. ROBERTS MJ, Chatfield MD, Hruby G, Nandurkar R, et al
    Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    BJU Int. 2022;130 Suppl 3:32-39.
    PubMed     Abstract available


    September 2022
  84. ELDRED-EVANS D, Connor MJ, Bertoncelli Tanaka M, Bass E, et al
    The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) prostate cancer diagnostic pathway.
    BJU Int. 2022 Sep 22. doi: 10.1111/bju.15899.
    PubMed     Abstract available


  85. VEERMAN H, Donswijk M, Bekers E, Bodar YJL, et al
    The Oncological Characteristics of Non-PSMA-Expressing Primary Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2022 Sep 19. doi: 10.1111/bju.15896.
    PubMed    


  86. EHRET F, Hofmann T, Furweger C, Kufeld M, et al
    Single-fraction PSMA-PET- and multiparametric MRI-guided SBRT for Prostate Cancer Local Recurrences.
    BJU Int. 2022 Sep 17. doi: 10.1111/bju.15894.
    PubMed     Abstract available


  87. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or coexistence?
    BJU Int. 2022 Sep 12. doi: 10.1111/bju.15074.
    PubMed    


  88. ORRASON AW, Styrke J, Garmo H, Stattin P, et al
    Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.
    BJU Int. 2022 Sep 11. doi: 10.1111/bju.15891.
    PubMed     Abstract available


  89. ICZKOWSKI KA, Molina M, Egevad L, Bostwick DG, et al
    Low-Grade Prostate Cancer Should Still be Labeled Cancer.
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15886.
    PubMed    


  90. ONG S, Chen K, Grummet J, Yaxley J, et al
    Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus?
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15883.
    PubMed     Abstract available


  91. MEIJER D, Ettema RH, van Leeuwen PJ, van der Kwast TH, et al
    The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
    BJU Int. 2022 Sep 7. doi: 10.1111/bju.15881.
    PubMed     Abstract available



  92. Updates on bladder, kidney and prostate cancers.
    BJU Int. 2022;130:275-276.
    PubMed    


  93. RAHOTA RG, Salin A, Gautier JR, Almeras C, et al
    A prehabilitation programme implemented before robot-assisted radical prostatectomy improves peri-operative outcomes and continence recovery.
    BJU Int. 2022;130:357-363.
    PubMed     Abstract available


    August 2022
  94. EXTERKATE L, Wegelin O, Barentsz JO, van der Leest MG, et al
    Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
    BJU Int. 2022 Aug 22. doi: 10.1111/bju.15876.
    PubMed     Abstract available


  95. SCHNEIDER A, Bulafka J, Arisi MF, Li L, et al
    Case of the month from the Thomas Jefferson Sidney Kimmel medical college, Philadelphia, USA. Prostatic abscess and advanced prostate cancer: considering malignancy in the differential diagnosis.
    BJU Int. 2022;130:181-185.
    PubMed    


    July 2022
  96. WILLIAMS IS, Perera S, Murphy DG, Corcoran NM, et al
    Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?
    BJU Int. 2022 Jul 25. doi: 10.1111/bju.15860.
    PubMed    


  97. RUSHWORTH LK, Loveridge C, Salji M, MacLeod M, et al
    Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer.
    BJU Int. 2022 Jul 18. doi: 10.1111/bju.15851.
    PubMed     Abstract available



  98. FDA approves new agent for the treatment of metastatic prostate cancer.
    BJU Int. 2022;130:3-4.
    PubMed    


  99. PARRY MG, Skolarus TA, Nossiter J, Sujenthiran A, et al
    Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes.
    BJU Int. 2022;130:84-91.
    PubMed     Abstract available


  100. SETIA SA, Smith J, Cendo D, Yoder J, et al
    Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
    BJU Int. 2022;130:54-61.
    PubMed     Abstract available


    June 2022
  101. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
    Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
    BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
    PubMed     Abstract available


  102. AGGARWAL A, Han L, Tree A, Lewis D, et al
    Impact of centralisation of prostate cancer services on the choice of radical treatment.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15830.
    PubMed     Abstract available


  103. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
    How and when should radiologists report T-staging on MRI in patients with prostate cancer?
    BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.
    PubMed    


  104. HARVEY M, Ong WL, Chao M, Udovicich C, et al
    Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
    BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
    PubMed     Abstract available


  105. LANGLEY S, Eden C, Perry M, Patil K, et al
    Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
    BJU Int. 2022;129:731-736.
    PubMed     Abstract available


  106. LAWRENTSCHUK N
    Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
    BJU Int. 2022;130 Suppl 1:4.
    PubMed    


  107. PERRY E, Talwar A, Taubman K, Ng M, et al
    Pathological predictors of (18) F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
    BJU Int. 2022;130 Suppl 1:28-36.
    PubMed     Abstract available


    May 2022
  108. O'BRIEN JS, McVey A, Kelly BD, Jenjitranant P, et al
    PSMA PET-CT Funding Grants Free Access to Superior Staging for Australian Men with Prostate Cancer.
    BJU Int. 2022 May 16. doi: 10.1111/bju.15773.
    PubMed    


  109. RAHOTA RG, Diamand R, Malavaud B, Fiard G, et al
    Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    BJU Int. 2022;129:621-626.
    PubMed     Abstract available


  110. HAYNE D, Grummet J, Espinoza D, McCombie SP, et al
    'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
    BJU Int. 2022;129:591-600.
    PubMed     Abstract available


    April 2022
  111. NATHAN A, Morris M, Parry MG, Berry B, et al
    Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15766.
    PubMed     Abstract available


  112. VAN RIEL LAMJG, Geboers B, Kabaktepe E, Blazevski A, et al
    Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15759.
    PubMed     Abstract available


  113. BOKU H, Kaneko M, Yamada Y, Morinaga Y, et al
    Microwave for focal therapy of prostate cancer: Non-clinical study and exploratory clinical trial.
    BJU Int. 2022 Apr 18. doi: 10.1111/bju.15749.
    PubMed     Abstract available


  114. LANE JA, Donovan JL, Young GJ, Davis M, et al
    Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study).
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15739.
    PubMed     Abstract available


  115. CHASE EC, Bryant AK, Sun Y, Jackson WC, et al
    Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients.
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15740.
    PubMed     Abstract available


  116. PTASZNIK G, Papa N, Kelly BD, Thompson J, et al
    High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer.
    BJU Int. 2022 Apr 1. doi: 10.1111/bju.15736.
    PubMed    



  117. Prostate cancer and ethnicity, personalised treatment for renal masses and oral testosterone for hypogonadism.
    BJU Int. 2022;129:422.
    PubMed    


  118. LUZZAGO S, Piccinelli ML, Mistretta FA, Bianchi R, et al
    Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
    BJU Int. 2022;129:524-533.
    PubMed     Abstract available


    March 2022

  119. New guidance regarding the diagnosis and risk stratification of patients with prostate cancer.
    BJU Int. 2022;129:304-305.
    PubMed    


  120. KLEIN RJ
    Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
    BJU Int. 2022;129:271.
    PubMed    


  121. FERRARO S, Biganzoli EM
    Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.
    BJU Int. 2022;129:418.
    PubMed    


  122. MARTIN RM, Dixon P, Turner E, Keeney E, et al
    Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.
    BJU Int. 2022;129:269-270.
    PubMed    


  123. TEYATEETI A, Grossman C, Kollmeier MA, Fiasconaro M, et al
    Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.
    BJU Int. 2022;129:337-344.
    PubMed     Abstract available


  124. BJORKLUND J, Stattin P, Ronmark E, Aly M, et al
    The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study.
    BJU Int. 2022;129:318-324.
    PubMed     Abstract available


  125. ZHAO J, Sun G, Zhu S, Dai J, et al
    Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    BJU Int. 2022;129:345-355.
    PubMed     Abstract available


  126. PASCHEN U, Sturtz S, Fleer D, Lampert U, et al
    Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    BJU Int. 2022;129:280-289.
    PubMed     Abstract available


    February 2022
  127. BODAR YJL, Veerman H, Meijer D, de Bie K, et al
    Standardised Uptake Values as Determined on PSMA PET/CT is associated with Oncological Outcomes in Prostate Cancer Patients.
    BJU Int. 2022 Feb 15. doi: 10.1111/bju.15710.
    PubMed     Abstract available


  128. DASON S, Vertosick EA, Udo K, Sjoberg DD, et al
    Clinical utility of subclassifying positive surgical margins at radical prostatectomy.
    BJU Int. 2022;129:194-200.
    PubMed     Abstract available


  129. SORCE G, Stabile A, Luciano R, Motterle G, et al
    Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
    BJU Int. 2022;129:201-207.
    PubMed     Abstract available


    January 2022
  130. NOSSITER J, Morris M, Parry MG, Sujenthiran A, et al
    Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15699.
    PubMed     Abstract available


  131. ONG WL, Thangasamy I, Murphy D, Pritchard E, et al
    Large variation in conservative management for low-risk prostate cancer in Australia and New Zealand.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15698.
    PubMed    


  132. BRATT O
    Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making.
    BJU Int. 2022;129:3-4.
    PubMed    


  133. GRAY WK, Day J, Briggs TWR, Harrison S, et al
    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
    BJU Int. 2022;129:93-103.
    PubMed     Abstract available


    December 2021
  134. RANNIKKO A, Leht M, Mirtti T, Kenttamies A, et al
    Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.
    BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
    PubMed     Abstract available


  135. SOORIAKUMARAN P, Wilson C, Rombach I, Hassanali N, et al
    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial.
    BJU Int. 2021 Dec 8. doi: 10.1111/bju.15669.
    PubMed     Abstract available


  136. VEERMAN H, Donswijk M, Bekers E, Olde Heuvel J, et al
    Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15664.
    PubMed     Abstract available



  137. Acute Urinary Retention and Cancer; Is It All About the Prostate?
    BJU Int. 2021;128:660.
    PubMed    


  138. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
    Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
    BJU Int. 2021;128:688-691.
    PubMed    


  139. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
    Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    BJU Int. 2021;128:702-712.
    PubMed     Abstract available


  140. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
    The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
    BJU Int. 2021;128 Suppl 3:45-51.
    PubMed     Abstract available


    November 2021
  141. JOHN JB, Pascoe J, Fowler S, Walton T, et al
    A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15656.
    PubMed     Abstract available


  142. ROSENBERG JE, Jung JH, Lee H, Lee S, et al
    Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer: a Cochrane Review.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15657.
    PubMed     Abstract available


  143. LEE V, An Y, Park HS, Yu JB, et al
    Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History.
    BJU Int. 2021 Nov 22. doi: 10.1111/bju.15650.
    PubMed     Abstract available


  144. KANNAN A, Clouston D, Frydenberg M, Ilic D, et al
    Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis.
    BJU Int. 2021 Nov 16. doi: 10.1111/bju.15647.
    PubMed     Abstract available


  145. HOFBAUER SL, Luger F, Harland N, Plage H, et al
    A Non-Inferiority Comparative Analysis of Micro-Ultrasound and MRI Targeted Biopsy in Men at Risk of Prostate Cancer.
    BJU Int. 2021 Nov 13. doi: 10.1111/bju.15635.
    PubMed     Abstract available


  146. IP CCK, Kealey J, Davis ID, Sengupta S, et al
    Impacts of the COVID-19 Pandemic on Early Detection of Prostate Cancer in Australia.
    BJU Int. 2021 Nov 9. doi: 10.1111/bju.15631.
    PubMed     Abstract available


  147. HEESTERMAN BL, van der Poel HG, Schoots IG, Mehra N, et al
    Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    BJU Int. 2021 Nov 6. doi: 10.1111/bju.15632.
    PubMed     Abstract available


  148. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
    Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
    BJU Int. 2021;128:555-557.
    PubMed    


  149. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
    Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    BJU Int. 2021;128:598-606.
    PubMed     Abstract available


  150. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
    Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
    BJU Int. 2021;128:615-624.
    PubMed     Abstract available


    October 2021
  151. HUYNH LM, Huang E, Towe M, Liang K, et al
    Evidence for integration of total and free testosterone levels in management of prostate cancer.
    BJU Int. 2021 Oct 30. doi: 10.1111/bju.15626.
    PubMed     Abstract available


  152. POULIOT F, Beauregard JM, Saad F, Trudel D, et al
    The 3TMPO study protocol: triple-tracer PET imaging of metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15621.
    PubMed     Abstract available


  153. WITT JH, Friedrich M, Jandrig B, Porsch M, et al
    Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
    BJU Int. 2021 Oct 17. doi: 10.1111/bju.15618.
    PubMed     Abstract available


  154. MARRA G, Calleris G, Marquis A, Oderda M, et al
    Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:524.
    PubMed    


  155. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
    Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:523.
    PubMed    


  156. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
    'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
    BJU Int. 2021;128:428-430.
    PubMed    


  157. KELLY R, Anton A, Wong S, Shapiro J, et al
    Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
    BJU Int. 2021;128 Suppl 1:18-26.
    PubMed     Abstract available


  158. CATHCART P, Ribeiro L, Moore C, Ahmed HU, et al
    Outcomes of the RAFT trial: robotic surgery after focal therapy.
    BJU Int. 2021;128:504-510.
    PubMed     Abstract available


    September 2021
  159. LIGHT A, Burns-Cox N, Maccormick A, John J, et al
    The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.
    BJU Int. 2021;128:298-300.
    PubMed    


    August 2021
  160. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
    Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
    PubMed     Abstract available


  161. MOROTE J, Schwartzmann I, Celma A, Roche S, et al
    The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
    BJU Int. 2021 Aug 10. doi: 10.1111/bju.15568.
    PubMed     Abstract available


  162. DOAN P, Graham P, Lahoud J, Remmers S, et al
    A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
    PubMed     Abstract available


  163. ISRAEL B, Immerzeel J, van der Leest M, Hannink G, et al
    Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer.
    BJU Int. 2021 Aug 6. doi: 10.1111/bju.15562.
    PubMed     Abstract available



  164. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
    BJU Int. 2021;128:127-130.
    PubMed    


  165. DUDDERIDGE TJ
    Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.
    BJU Int. 2021;128:125-126.
    PubMed    


  166. INOUE T, Sasaki T, Kato M, Masui S, et al
    Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    BJU Int. 2021 Aug 1. doi: 10.1111/bju.15561.
    PubMed     Abstract available



  167. Chemotherapeutic treatment of MCRPC and non-MCRPC.
    BJU Int. 2021;128:153-154.
    PubMed    


  168. TAMIR S, Hermann D, Margel D, Gavrielli S, et al
    Indications for prostate multiparametric magnetic resonance imaging: changes over 7 years in a single referral centre.
    BJU Int. 2021;128:165-167.
    PubMed    


    July 2021
  169. BUELENS S, Poelaert F, Claeys T, De Bleser E, et al
    Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study.
    BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553.
    PubMed     Abstract available


  170. KAMRAN SC, Zietman AL
    Radiation Treatment in Prostate Cancer: Covering the Waterfront.
    BJU Int. 2021 Jul 17. doi: 10.1111/bju.15550.
    PubMed     Abstract available


  171. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
    Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
    PubMed     Abstract available


  172. BENAFIF S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al
    The BARCODE1 Pilot: a feasibility study of using germline SNPs to target prostate cancer screening.
    BJU Int. 2021 Jul 2. doi: 10.1111/bju.15535.
    PubMed     Abstract available


  173. MOTTRIE A, Mazzone E, Wiklund P, Graefen M, et al
    Objective assessment of intraoperative skills for robot-assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative.
    BJU Int. 2021;128:103-111.
    PubMed     Abstract available


  174. SINGH S, Sandhu P, Beckmann K, Santaolalla A, et al
    Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    BJU Int. 2021;128:72-78.
    PubMed     Abstract available


    June 2021
  175. MORI K, Mostafaei H, Sari Motlagh R, Pradere B, et al
    Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis.
    BJU Int. 2021 Jun 25. doi: 10.1111/bju.15507.
    PubMed     Abstract available


  176. BERTONCELLI TANAKA M, Sahota K, Burn J, Falconer A, et al
    Prostate cancer in transgender women: what does a urologist need to know?
    BJU Int. 2021 Jun 22. doi: 10.1111/bju.15521.
    PubMed     Abstract available


  177. ALBERTSEN P
    Prostate cancer: the interplay between genetics and the environment.
    BJU Int. 2021;127:615-616.
    PubMed    


  178. YAXLEY J
    Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
    BJU Int. 2021;127:747.
    PubMed    


  179. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    PubMed    


  180. TANDOGDU Z, Collins J, Shaw G, Rohn J, et al
    Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
    BJU Int. 2021;127:729-741.
    PubMed     Abstract available


  181. DINNEEN E, Haider A, Grierson J, Freeman A, et al
    NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial.
    BJU Int. 2021;127:676-686.
    PubMed     Abstract available


    May 2021
  182. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
    ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
    PubMed     Abstract available


  183. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
    Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
    PubMed     Abstract available


  184. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
    Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
    BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
    PubMed     Abstract available


  185. O'CALLAGHAN M, Papa N, Pase M, Frydenberg M, et al
    Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?
    BJU Int. 2021 May 11. doi: 10.1111/bju.15366.
    PubMed    



  186. Recent advances in the diagnosis and management of prostate cancer.
    BJU Int. 2021;127:518-519.
    PubMed    


  187. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
    Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2021;127:524-527.
    PubMed    


  188. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
    Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2021;127:560-566.
    PubMed     Abstract available


  189. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
    A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
    BJU Int. 2021;127:575-584.
    PubMed     Abstract available


  190. TIMM B, Farag M, Liodakis P, Angus D, et al
    Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    BJU Int. 2021;127 Suppl 1:23-29.
    PubMed     Abstract available


  191. JOHN A, John H, Catterwell R, Selth LA, et al
    Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis.
    BJU Int. 2021;127 Suppl 1:13-22.
    PubMed     Abstract available


    April 2021
  192. CHILUKURI S, Murthy V
    Adjuvant radiation for prostate cancer: Too early to abandon?
    BJU Int. 2021 Apr 9. doi: 10.1111/bju.15422.
    PubMed     Abstract available


  193. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.
    BJU Int. 2021 Apr 3. doi: 10.1111/bju.15417.
    PubMed     Abstract available


  194. XU AJ, Taylor J, Gao T, Mihalcea R, et al
    TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.
    BJU Int. 2021 Apr 2. doi: 10.1111/bju.15403.
    PubMed     Abstract available


  195. GALFANO A, Secco S, Dell'Oglio P, Rha K, et al
    Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents.
    BJU Int. 2021;127:412-417.
    PubMed     Abstract available


    March 2021
  196. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
    Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
    BJU Int. 2021;127:304-306.
    PubMed    


  197. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
    Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
    BJU Int. 2021;127:361-368.
    PubMed     Abstract available


    February 2021
  198. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
    Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
    BJU Int. 2021;127:190-197.
    PubMed     Abstract available


    January 2021
  199. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
    'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
    BJU Int. 2021;127:37-40.
    PubMed    



  200. World News.
    BJU Int. 2021;127:1-3.
    PubMed    


  201. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
    Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
    BJU Int. 2021;127:114-121.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.